$WVE

Tan Aik Na sold $3K of WVE

Tan Aik Na sold 432 shares of Wave Life Sciences, Inc. (WVE) at $6.01 on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tan Aik Na
Published Aug 14, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WVE
Neutral
high confidence
Mentioned
$WVE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WVENeutralLow
01

Why it matters

The disclosed sale is small in dollar terms ($2,596.32) and explicitly under a pre-arranged 10b5-1 plan, which generally limits interpretive weight for near-term trading decisions.

02

Market read

Traders may note the planned insider selling, but there is no accompanying fundamental update in the text.

03

What to watch

The article does not disclose any change in business outlook, guidance, or material corporate events, so the signal-to-noise is low.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-13 after-hours; transaction dated 2026-08-11

Background

This is an SEC Form 4 insider transaction disclosure for Wave Life Sciences, reported by a director.

Company-level read

Ticker impact

$WVENeutralHigh confidence
Context

Wave Life Sciences director Tan Aik Na sold 432 shares at $6.01 under a pre-arranged 10b5-1 plan, per a fresh Form 4 filing.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a standard open-market sale coded as S and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a small, planned insider sale.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with internal risk management or liquidity needs, so traders may still watch for follow-on insider activity.

Key entities

  • Wave Life Sciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tan Aik Na

    Director who sold 432 shares at $6.0100/share under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WVEHigh

Wave Life Sciences initiated with a Buy at UBS

UBS initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $11 price target, citing its leadership in RNA editing therapeutics and positive proof of concept data. SK Hynix (SKHY) seeks U.S. approval to ship more chipmaking equipment to its Dalian, China factory, linked to its subsidiary Solidigm's plans for a new U.S. NAND memory factory and potential 2027 IPO.

$WVEHighAI 8/10

Wave Life Sciences reaches FDA alignment on WVE-006 trial design

Wave Life Sciences (WVE) aligned with the FDA on the trial design for WVE-006, an investigational treatment for alpha-1 antitrypsin deficiency. The company plans a two-year trial with a one-year interim analysis for potential accelerated approval, using its current assay method. WVE-006 is in Phase 1b/2a trials, with data expected in Q4 2026. The treatment aims to address a rare genetic disorder affecting 200,000 people in the U.S. and Europe.

$WVEMedAI 8/10

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

Wave Life Sciences (WVE) reported FDA alignment on a registrational pathway for WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year trial with a one-year interim analysis for potential accelerated approval. WVE-006 aims to treat both lung and liver manifestations of AATD with infrequent subcutaneous dosing. Wave expects to share data from the RestorAATion-2 trial in Q4 2026.